Skip to main content

UPLIZNA (Amgen Australia Pty Ltd)

Product name
UPLIZNA
Date registered
Evaluation commenced
Decision date
Approval time
166 (175 working days)
Active ingredients
inebilizumab
Registration type
NCE/ NBE
Indication

Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.

Help us improve this page